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Can Scarred Hearts Be Repaired?
MG Biotherapeutics Is Testing Cell Therapy
for Heart Repair
In a myocardial infarction, more com- a
monly known as a heart attack, f
heart cells die from a lack of oxy- h
gen. Just as in a simple cut, scar e
tissue forms. This scar tissue does m
not contract and does not have the s
strength of the heart muscle tissue. D
As a result, the heart enlarges and B
loses its ability to pump blood effi-
ciently. This condition, known as c
congestive heart failure, is pro- t
gressively fatal. Currently, only the V
symptoms of congestive heart fail- B
ure can be treated by drugs or sur- b
gery. There is no cure because heart u
tissue does not spontaneously re- c
generate and no manner of induc-
ing it to do so exists. According to
the American Heart Association’s “2004 figures, over five million Ameri-
cans experienced congestive heart b
failure that year. t
In a new treatment undergoing a
mlarge clinical trial, muscle cells
biopsied from patients’ own thigh n
muscles are implanted in the dam- d
aged tissue in an attempt to at least
lpartially mend damaged hearts. This
innovation comes from MG Biother- t
apeutics, a 50-person virtual joint f
venture inaugurated in 2004 by Bos-
aton-based Genzyme and Minnea-
polis medical device company Med- b
tronic. iGenzyme brings extensive ex-
bperience in cell therapy to the part-
nership, and Medtronic has wide
expertise in conventional cardiol-
ogy treatments. Genzyme already
Mhas two autologous cell-therapy
iproducts on the market: Epicel (cul-
etured epidermal autografts) skin re-
bplacement, which is grown from se-
bverely burned patients’ own skin
dcells to eliminate tissue rejection,
jand Carticel (autologous cultured
schondrocytes), which repairs dam-
gaged knee cartilage. Medtronic’s
wcardiology portfolio includes devices
Asuch as catheters, stents, heart
dvalves, and pacemakers. However,
oMedtronic has been following the
potential of skeletal myoblast cells ls a method of improving heart p
unction since the mid-eighties. “We d
ave had a program for years on c
lectronically stimulating skeletal i
uscle wrapped around the heart,” m
ays Dr. Maura Donovan, Clinical s
irector of BioSciences R&D and c
akken Fellow at Medtronic.
MG Biotherapeutics is faced with c
ompetition from research institu- p
ions and commercial rivals such as “
ascular Genetics in North Carolina, t
ioHeart in Florida, and Maryland- s
ased GenVec, which has teamed R
p with Johnson & Johnson for G
atheter expertise. dc
a
sPart of the hypothesis
ehind cell therapy is h
rhat implanted skeletal
gyoblasts, which ordi-
m
arily heal muscle as it is e
mamaged, may spur re-
iease of cytokines, pro-
s
eins that signal an in- “
alammatory process to
tctivate wound healing,
v
lood cell growth, and, it o
es hoped, proliferation of
Dlood vessels.”
h
f
dIn a phase II clinical trial dubbed
sAGIC (Myoblast Autologous Graft
cn Ischemic Cardiomyopathy), skel-
ttal myoblast (muscle) cells will be
miopsied from patients’ legs. After
reing expanded in the lab for 21
says, the cells will be directly in-
aected into and around the scar tis-
gue during bypass surgery. A control
eroup of patients will be injected
ith a placebo of transfer media.
aprevious ten-patient trial con-
cucted by Dr. Phillippe Menasche
tf the Department of Cardiovascu-
ar Surgery at the Hospital Euro- hean George Pompidou in Paris in-
icated that grafting the muscle
ells onto the damaged tissue can
mprove heart function. Menasche
easured metabolic activity by PET
cans as well as ultrasound to
heck behavior of the tissue.
So far, 78 patients have been re-
ruited for the MAGIC trial, which is
rojected to have 300 participants.
All the patients have suffered rela-
ively large infarcts [scarring]. The
car has to be well healed,” says Dr.
alph Kelly, VP of Clinical Affairs at
enzyme. The trial is being con-
ucted in European countries, in-
luding France, Belgium, the UK,
nd Germany, under the supervi-
ion of Dr. Menasche.
After a heart attack, the remaining
eart tissue takes up the load. As a
esult, the “overworked” heart de-
enerates more quickly than nor-
al. Overall heart function declines
xponentially. The aim of this treat-
ent is to arrest this heart-remodel-
ng process and reduce the body’s
tress response to the damage.
There are also very high levels of
drenaline in the blood released by
he brain and the sympathetic ner-
ous system,” said Kelly. “It is anal-
gous to severe dehydration or the
volutionary fight or flight response.
octors currently give drugs after a
eart attack to ‘dial down the heart
unction’ in order to slow the degra-
ation of the remaining heart tis-
ue.” Part of the hypothesis behind
ell therapy is that implanted skele-
al myoblasts, which ordinarily heal
uscle as it is damaged, may spur
elease of cytokines, proteins that
ignal an inflammatory process to
ctivate wound healing, blood-cell
rowth, and, hopefully, angiogen-
sis (proliferation of blood vessels).
The skeletal muscle cells do not
ctually differentiate into heart mus-
le or convey electrical impulses
he way heart cells do, but they may
elp bolster a flabby heart structur-
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direct electrical connection be- i
tween the implanted cells and the v
rest of the heart, it does not mean c
that the cell does not contract in q
synchronicity with the heart. “It may a
be that the stretch of the muscles is t
enough,” says Kelly. c
MG Biotherapeutics is currently t
focusing on skeletal muscle cells o
because “they have been studied “
extensively preclinically and have i
been shown to be resistant to con- f
ditions of hypoxic stress,” says Dr. i
Maura Donovan who adds that scar s
tissue is poorly perfused with oxy- s
gen-rich blood.
Trials conducted on animals con- h
firm that about 10% of the injected p
cells survive. “Numerous laboratory d
studies have been done on animals, l
but it is extremely hard to conduct j
controlled studies in humans,” says c
Dr. Gordana Vunjak-Novakovic, Prin- t
cipal Research Scientist at the Mas- g
sachusetts Institute of Technology. i
A key issue is cell localization, i
which is how many cells go to the r
right place. How many stay there in- a
stead of migrating out or dying? If D
the dead muscle [scar tissue of the
heart] becomes fibrous and stiff, it m
is a substrate for cells to adhere to w
but is not optimal.” t
Donovan explains that the mecha- o
nism of action by which transplanted t
cells may improve the function of i
scarred heart tissue is unclear; in c
the end, it may be a combination of h
many factors. “One theory is that w
transplanting cells into the myocar- t
dium may promote an angiogenic “
response and improve tissue perfu- t
sion,” she says. “An alternative the-
e
ory is that transplanted cells may
s
secrete factors that recruit native
pstem cells into the area to repair tis-
tsue.” The transplanted cells may
hprevent deleterious tissue remodel-
Iing. Interestingly, in transmyocardial
wrevascularization procedures (TMR
iand PMR) clinicians improve blood
cperfusion and heart function by li-
aterally poking holes in the heart. In
current clinical cell-therapy trials, sur-
vgeons implant cells into the heart
dvia multiple injections, which may
igenerate a positive response by
aincreasing the blood flow to the af-
ofected area just like mechanically
iperforating scar tissue but have lit-
dtle to do with the cells themselves.
r“Current clinical studies are fo-
cused on determining the safety af transplanting therapeutic cells
nto infarcted myocardium,” Dono-
an says. “Complementary preclini-
al studies are needed to answer
uestions related to mechanism of
ction and to determine the fate of
he transplanted cells.” In preclini-
al controlled experiments, MG Bio-
herapeutics will look at what is the
ptimal way of delivering the cells.
Two things appear to be happen-
ng when you inject cells into in-
arcted tissue,” Donovan says. “One
s you get physical loss of cells. The
econd is not all the cells you inject
urvive in that location.”
More than one research group
ave raised questions about the im-
act of the vast amount of cellular
ebris left over from the 90% of bil-
ions of cells that die after being in-
ected into the heart. The debris
ould generate a helpful inflamma-
ory response by stimulating angio-
enesis or a harmful one by damag-
ng healthy tissue. “You are injecting
nto the infarct. The inflammation
esponse would be different if you
re injecting into normal tissue,”
onovan explains.
Another issue is that skeletal
uscle cells that do not integrate
ith existing heart tissue may not
ransmit cardiac electrical impulses
r, even worse, may respond to
he electrical impulses of the heart
n a completely different way. This
ould cause arrhythmias, or irregular
eartbeats. This was not the case
ith animals, but there is concern
hat this could happen in humans.
There was early clinical evidence
hat there might be more arrhythmic
vents in these patients,” Donovan
ays. “But the problem is that the
atient population we are treating in
hese clinical studies is already at a
igh risk of ventricular arrhythmias.
t is really unclear from current data
hether the myoblast implantation
s increasing that risk. Subsequent
linical studies will be needed to
nswer this question.”
MG Biotherapeutics is also de-
eloping a portfolio of devices to
eliver cells to the heart in a less
nvasive way, says Genzyme’s Kelly,
nd the company is already working
n the next generation therapies,
ncluding genetically modified cells,
onor cells, and advanced biomate-
ials that will help cells stick better
nd live longer.Wendy Wolfson (wendywolfson@nasw.org)
is a science and technology writer based in
Oakland, CA.
